Novo Nordisk stock slides Monday on second-generation GLP-1 data
Novo Nordisk ( NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its ...
Novo Nordisk's new obesity drug trial data disappoints again
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
Novo Nordisk: CagriSema Disappoints Again
Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...
BioPharma Dive5h
Novo’s Wegovy successor disappoints in second large trial
A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...
Novo Nordisk Stock Slides After Obesity Drug Trial Disappoints
Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in ...
Novo Nordisk under pressure as obesity drug disappoints in diabetes trial
Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.
Endpoints News7h
Mired in low ex­pec­ta­tions, No­vo braces for up­com­ing Ca­griSe­ma head-to-head tri­al
Novo Nordisk's CagriSema looks barely better than Eli Lilly's Zepbound in patients with obesity and diabetes, lowering expectations ahead of crucial head-to-head study ...
MarketBeat on MSN7h
Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors
Novo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are ...